The Advent of IL-17A Blockade in Ankylosing Spondylitis: Secukinumab, Ixekizumab and Beyond

Expert Review of Clinical Immunology - United Kingdom
doi 10.1080/1744666x.2019.1561281
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Correction To: Secukinumab: A Review in Ankylosing Spondylitis

Drugs
Pharmacology
2019English

Cost-Effectiveness Analysis of Secukinumab in Ankylosing Spondylitis: A Canadian Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Secukinumab: First IL-17A Antagonist for Plaque Psoriasis

Pharmacy Today
2015English

Genetics in Ankylosing Spondylitis – Beyond HLA-B*27

2012English

Real-World Data on Secukinumab Use for Psoriatic Arthritis and Ankylosing Spondylitis

Therapeutic Advances in Musculoskeletal Disease
RheumatologyOrthopedicsSports Medicine
2019English

The Seroconversion Rate of QuantiFERON-TB Gold In-Tube Test in Psoriatic Patients Receiving Secukinumab and Ixekizumab, the Anti-Interleukin-17a Monoclonal Antibodies

PLoS ONE
Multidisciplinary
2019English

IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications

Frontiers in Immunology
AllergyImmunology
2020English

Relapsing Polychondritis Following Treatment With Secukinumab for Ankylosing Spondylitis: Case Report and Review of the Literature

Case Reports in Rheumatology
2018English

Ankylosing Spondylitis

2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy